EP1862537A1 - Ohne aus tieren stammende bestandteile kultivierbare zelline, verfahren zu deren realisierung, verfahren zur virusherstellung unter verwendung der zellinie sowie impstoffherstellungsverfahren - Google Patents

Ohne aus tieren stammende bestandteile kultivierbare zelline, verfahren zu deren realisierung, verfahren zur virusherstellung unter verwendung der zellinie sowie impstoffherstellungsverfahren Download PDF

Info

Publication number
EP1862537A1
EP1862537A1 EP05720511A EP05720511A EP1862537A1 EP 1862537 A1 EP1862537 A1 EP 1862537A1 EP 05720511 A EP05720511 A EP 05720511A EP 05720511 A EP05720511 A EP 05720511A EP 1862537 A1 EP1862537 A1 EP 1862537A1
Authority
EP
European Patent Office
Prior art keywords
virus
medium
cells
cell
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05720511A
Other languages
English (en)
French (fr)
Other versions
EP1862537A4 (de
EP1862537B1 (de
Inventor
Masami Mochizuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoritsu Seiyaku Corp
Original Assignee
Kyoritsu Seiyaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoritsu Seiyaku Corp filed Critical Kyoritsu Seiyaku Corp
Publication of EP1862537A1 publication Critical patent/EP1862537A1/de
Publication of EP1862537A4 publication Critical patent/EP1862537A4/de
Application granted granted Critical
Publication of EP1862537B1 publication Critical patent/EP1862537B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18451—Methods of production or purification of viral material

Definitions

  • the present invention relates to a cell strain capable of being cultured without ingredients derived from animals and a method of producing the same.
  • the present invention also relates to a method of producing a virus using the above cell strain, a method of producing a diagnostic antigen, and a method of producing a vaccine.
  • the present invention also relates to a medium used for the culture of the above cell strain.
  • the present invention also relates to a medium used for cryopreservation of the above cell strain and a cryopreservation method.
  • a half-century or more has passed since the creation of a technique of culturing animal cells and the like in a test tube. Such a technique has been significantly developed together with progression of science and technology.
  • cell growth factor As a nutrient, it has been necessary for cell division and replication to additionally supply a "cell growth factor" as a nutrient.
  • a cell growth factor include various types of hormones, insulin, putrescine, and a fibroblast growth factor.
  • cell growth factors have not yet been clarified in all cell species, and unknown ingredients are included in many cases.
  • animal serums instead of cell growth factors, animal serums can be used. The effects thereof can be non-specifically anticipated.
  • bovine serum is usually selected because of a large bovine population and also because it can be stably supplied.
  • fetal bovine serum has been frequently used because it contains only a small amount of toxic protein.
  • a bovine-derived protein may be contained in a test material, although bovine is not an animal species of interest.
  • the use of such a bovine-derived protein as a pharmaceutical for a human or other animal species may cause a problem.
  • the first problem is related to allergy.
  • a vaccine or a drug that contains bovine serum is parenterally injected into a human, or animals
  • a first injection may not cause a problem in many cases.
  • a second injection or later injections may cause a problem regarding an allergy reaction.
  • This phenomenon can be immunologically explained. That is, an animal only slightly reacts with a high-molecular substance (e.g. a protein having a molecular weight of 10,000 daltons or more) when the substance is exposed to the animal for the first time, and thus the administered substance is decomposed in vivo.
  • a memory regarding exposure remains in immune system.
  • the second problem is related to the contamination of pathogens or bovine serum antibodies contained in bovine serum.
  • a famous example is contamination with Pestivirus, Retrovirus, Mycoplasma, etc. of bovine origin.
  • BSE bovine spongiform encephalopathy
  • bovine serum may occasionally cause troublesome occurrences
  • bovine serum has commonly been used for the production of vaccines particularly used for a veterinary field that targets animals over the world.
  • media disclosed in these publications comprised unknown ingredients, or although they are serum-free, they comprised animal-derived ingredients.
  • a simple cryopreservation method of cells cultured in a serum free medium a method comprising adding 10% of dimethyl sulfoxide (DMSO) to an MDSS2 medium (AXCELL Biotechnologies, F-69610 Saint Genis l'Arentiere) that is one type of SFM, and then cryopreserving Vero cells as monkey kidney-derived cells and BHK-21 cells as hamster kidney-derived cells using the produced medium, has been reported.
  • DMSO dimethyl sulfoxide
  • an MDSS2 medium AXCELL Biotechnologies, F-69610 Saint Genis l'Arentiere
  • Vero cells as monkey kidney-derived cells and BHK-21 cells as hamster kidney-derived cells using the produced medium
  • One aspect of the present invention relates to a cell strain induced from MDCK cells as dog kidney-derived cells, which can be cultured without ingredients derived from animals.
  • This cell strain may be either a cell strain deposited under accession No. FERM BP-10225, or a cell strain having biological properties equivalent to those of the above cell strain.
  • one aspect of the present invention relates to a method of producing a cell strain, which comprises a step of adapting MDCK cells to a medium that does not contain a serum but contains a cell growth factor and a step of culturing the cells in a medium that contains an RPMI 1640 medium and a soybean-derived peptone but does not contain ingredients derived from animals, so as to produce a cell strain that can be cultured without ingredients derived from animals.
  • one aspect of the present invention relates to a method of producing a virus, which comprises a step of infecting a cell strain with a virus and a step of culturing the infected cell strain to replicate the virus.
  • a medium used for the culture of the infected cell strain may be a medium that contains an RPMI 1640 medium and a soybean-derived peptone but does not contain ingredients derived from animals.
  • a suspension culture method may be used for the culture of the infected cell strain.
  • a virus used herein may be one selected from the group consisting of Paramyxoviridae, Orthomyxoviridae, Rhabdoviridae, Flaviviridae, Caliciviridae, Adenoviridae, Herpesviridae, and Parvoviridae.
  • the virus used herein may also be one selected from the group consisting of canine distemper virus, measles virus, canine parainfluenza virus, SV5 virus, influenza virus, rabies virus, Japanese encephalitis virus, canine calicivirus, canine adenovirus type 1 and type 2, human adenovirus, canine herpesvirus, and canine parvovirus type 1 and type 2.
  • one aspect of the present invention relates to a method of producing a diagnostic antigen using a virus produced by the aforementioned method.
  • one aspect of the present invention relates to a method of producing a vaccine using a virus produced by the aforementioned method.
  • one aspect of the present invention relates to a medium that contains an RPMI 1640 medium and a soybean-derived peptone but does not contain ingredients derived from animals.
  • one aspect of the present invention relates to a medium used for cryopreservation of cells, which is produced by adding 10% by weight of dimethyl sulfoxide to the above medium.
  • one aspect of the present invention relates to a cryopreservation method, which comprises a step of cryopreserving a cell strain induced from MDCK cells as dog kidney-derived cells, which can be cultured without ingredients derived from animals, using the aforementioned medium used for cryopreservation of cells.
  • a cell strain induced from MDCK cells is cultured without ingredients derived from animals, when a virus produced using such a cell strain is used as a vaccine or test reagent, it is possible to provide a safe vaccine or test reagent.
  • a virus can be replicated using a commercially available inexpensive medium, when a virus is produced using such a medium, it is possible to provide an inexpensive vaccine or test reagent.
  • a medium does not contain ingredients derived from animals, when cells infected with a virus are cultured in the above medium, it is possible to provide a safe vaccine or test reagent.
  • cells can be frozen using a medium that does not contain ingredients derived from animals, it is possible to provide a safe vaccine or test reagent.
  • ingredients derived from animals and “without ingredients derived from animals” are used in the present specification to particularly mean that a medium does not contain an animal-derived protein ingredient that can be a cause of allergy.
  • an ingredient that can be a cause of allergy include an animal-derived serum, a serum albumin as a portion of the above serum, an animal protein such as a cell growth factor, and various types of additives derived from animals (Bacto peptone, Tryptose phosphate broth, etc.).
  • an MDCK cell that is a dog kidney cell system having a wider virus infection spectrum is first selected.
  • a commercially available basal medium that does not contain ingredients derived from animals such as Eagle's MEM, RPMI 1640 medium, or Leiovitz's L-15 medium, is used, such MDCK cells do not replicate unless bovine serum is added to the medium. Accordingly, MDCK cells are adapted and subcultured serially.
  • MDCK cells are adapted to a serum free medium that contains a cell growth factor.
  • a cell growth factor an epidermal growth factor is preferable.
  • a recombinant epidermal growth factor may also be used.
  • Specific examples of such a medium include "Opti-Pro SFM" as a product name (Invitrogen; Catalogue No. 12309-019) and "Opti-MEM I Reduced-Serum Medium” as a product name (Invitrogen; Catalogue No. 31985) that is a modified Eagle's MEM, but examples are not limited thereto.
  • Adaptation of MDCK cells is carried out until replication of the cells is stabilized.
  • the MDCK cells are then adapted to a medium that contains an RPMI 1640 medium and a soybean-derived peptone but does not contain ingredients derived from animals (hereinafter referred to as an "RPMI/SP medium).
  • a soybean-derived peptone is a non-animal peptone and acts as a source of protein.
  • the content of such a soybean-derived peptone in the medium is preferably between 250 ⁇ g/ml and 3,000 ⁇ g/ml, more preferably between 500 ⁇ g/ml and 1,000 ⁇ g/ml, and particularly preferably approximately 750 ⁇ g/ml.
  • the content of a protein in the medium is preferably 20 ⁇ g/ml or less, more preferably 10 ⁇ g/ml or less, and particularly preferably 5 ⁇ g/ml or less.
  • composition of an RPMI/SP medium which contains 750 ⁇ g/ml soybean peptone, is shown below, but examples are not limited thereto.
  • the MDCK-SP cell strain is infected with a virus that is sensitive to the MDCK cell strain, and the thus infected cell strain is cultured and replicated, so that the virus can be produced.
  • a medium used for the culture of such virus a medium that does not contain ingredients derived from animals is preferable, and the aforementioned RPMI/SP medium is more preferable.
  • Known methods can be used in the culture of the infected cell strain. Examples of such known methods include a monolayer culture method and a suspension culture method.
  • such a monolayer culture method comprises infecting cells that have been monolayer-cultured in the inner surface of a vessel with a virus of interest and then subjecting the infected cells to a standing culture or a roll-streak culture, so as to prepare the virus in the culture supernatant.
  • a vessel a plate culture vessel or a roll-streak culture flask can be used, for example.
  • Specific examples of such a vessel include a Petri dish and a T flask.
  • a material of such a vessel a non-glass material is preferable, and a plastic is more preferable.
  • An example of the suspension culture method is a microcarrier method using microcarrier beads.
  • a microcarrier method comprises allowing cells to replicate in the form of a monolayer on the surfaces of microcarrier beads in a bioreactor (culture tank), and then infecting the cells replicated on the microcarrier beads with viruses, followed by culturing while stirring, so as to prepare viruses of interest in the culture solution.
  • materials of such microcarrier beads include ceramic, dextran, glass, silicon, plastic, and polyacrylamide.
  • Cytodex (trade mark) 1 manufactured by Amersham Bioscience can be used, for example.
  • viruses sensitive to MDCK-SP cells include, but not limited to, Rhabdoviridae, Poxviridae, Picornaviridae, Reoviridae, Adenoviridae, Caliciviridae, Adenoviridae, Paramyxoviridae, Orthomyxoviridae, Flaviviridae, Herpesviridae, and Parvoviridae.
  • preferred viruses that are able to easily adaption are viruses belonging to Paramyxoviridae, Orthomyxoviridae, Rhabdoviridae, Flaviviridae, Caliciviridae, Adenoviridae, Herpesviridae, and Parvoviridae.
  • Preferred viruses further include canine distemper virus, measles virus, canine parainfluenza virus, SV5 virus, influenza virus, rabies virus, Japanese encephalitis virus, canine calicivirus, canine adenovirus type 1 and type 2, human adenovirus, canine herpesvirus, and canine parvovirus type 1 and type 2. If a technique of acclimatizing viruses to the cultured cells, which is known as "adaptation,” were used, the sensitivity spectrum of MDCK-SP cells could be extended.
  • a virus produced by the method of the present invention is recovered and purified, so that it can be used for a vaccine or a diagnostic antigen substance.
  • known methods can be used. For example, cells are frozen and then thawed to disrupt them, and the thawed solution is then centrifuged to eliminate cells or disrupted cell debris, so that the supernatant may be recovered as a virus stock.
  • the produced vaccine may be either an inactivated vaccine or a live vaccine.
  • the recovered and purified virus may be inactivated with formalin or the like, and an adjuvant may be added to the thus inactivated virus.
  • an attenuated virus may be produced, and it may be then recovered and purified. Thereafter, an adjuvant may be added to the resultant virus.
  • the viral level in a vaccine should be a level sufficient for imparting to a dog to which the vaccine is to be administered, immunity that is necessary for inhibiting infection with the virus as a target.
  • such a viral level is between 1 ⁇ 10 3.5 TCID 50 /ml and 1 ⁇ 10 5.0 TCID 50 /ml, or more.
  • An example of the adjuvant used herein is an adjuvant that is able to impart systemic infection protective immunity or local infection protective immunity to a dog to which the vaccine is to be administered.
  • the inactivated virus as stated above is used as an antigen, or an antigen isolated from a virus is fixed on a supporting medium such as an ELISA plate or a nitrocellulose membrane, so as to prepare the diagnostic agent.
  • a diagnostic agent is allowed to bind to an antibody existing in the serum of a dog. Thereafter, they are allowed to react with a secondary antibody to which horseradish peroxidase or alkaline phosphatase has bound, and it is then subjected to a known reaction such as a color reaction, so that it can be visualized.
  • a circulating antibody existing in a dog infected with various types of viruses namely, the presence or absence of infection, can be detected and confirmed.
  • a medium produced by adding dimethyl sulfoxide (DMSO) to the RPMI/SP medium of the present invention can be used.
  • the amount of DMSO contained in the RPMI/SP medium is preferably between 10% and 20% by weight, and more preferably approximately 10% by weight, based on the weight of the above medium.
  • DMSO dimethyl sulfoxide
  • the medium of the present invention which is used in cryopreservation of cells, contains neither serum nor any other ingredients derived from animals, it is suitably used in low-temperature preservation of cells adapted to a serum free medium.
  • the medium of the present invention is preferable as a medium used in cryopreservation of the MDCK-SP cells.
  • MDCK cells used as dog kidney-derived cells in the present example are related to a cell system produced from the kidney of a healthy female cocker spaniel by Madin & Darby on September 1958. It is considered that this cell system is derived from cells (ATCC No. CCL-34) registered with ATCC (American Type Culture Collection).
  • ATCC No. CCL-34 registered with ATCC (American Type Culture Collection).
  • the inventor of the present application used these cells for studies in the Lab. of Veterinary Microbiology, Department of Veterinary Medicine, Faculty of Agricultural, the University of Tokyo. Thereafter, the same above cells were transferred to the Lab. of Veterinary Microbiology, Department of Veterinary Medicine, Faculty of Agricultural, Kagoshima University, and were then transferred to the Lab. of Clinical Microbiology, Kyoritsu Seiyaku Corp. In the Lab.
  • the cells were subcultured in a medium (7.5% MEM) produced by adding 7.5% fetal bovine serum, 10% tryptose phosphate broth, and L-glutamine (0.292 g/l), and for the purpose of prevention of bug's contamination, also adding penicillin (100 U/ml), streptomycin (100 ⁇ g/ml), and amphotericin B (0.25 to 0.5 ⁇ g/ml), to an Eagle's MEM basal medium (manufactured by Nissui Pharmaceutical Co., Ltd.; Eagle MEM medium (Nissui (1)). These were defined as parent cells.
  • a medium (7.5% MEM) produced by adding 7.5% fetal bovine serum, 10% tryptose phosphate broth, and L-glutamine (0.292 g/l), and for the purpose of prevention of bug's contamination, also adding penicillin (100 U/ml), streptomycin (100 ⁇ g/ml), and amphotericin B (0.25 to 0.5
  • the cells were subcultured in a serum free medium containing a recombinant epidermal growth factor, the product name of which was "Opti-Pro SFM" (Invitrogen; Catalogue No. 12309-019), until the passage number reached 2. Thereafter, the culture solution was exchanged with a modified Eagle's MEM having a product name "Opti-MEM I Reduced-Serum Medium” (Invitrogen; Catalogue No. 31985). In this medium, the cells were subcultured with no addition of fetal bovine serum, until the passage number reached 33. Basically, the cells were treated under the same subculture conditions as those of the parent cells.
  • the original cells were subcultured to quantities that were 4 times the initial quantities at the intervals of approximately 7 days.
  • the cell surfaces were washed twice with a 0.25% trypsin + 0.02% EDTA (ethylenediaminetetraacetic acid) solution, and the cells were then left at rest in an incubator at 37°C, so that the cells were dispersed.
  • the used trypsin was swine pancreas-derived DIFCO TRYPSIN 250 (Nippon Becton Dickinson Co., Ltd.).
  • the above trypsin was dissolved in sterilized PBS and was then filtrated through a 220-nm filter for sterilization.
  • cell growth was delayed at times.
  • the medium was exchanged with a fresh medium one or two times, or the expanding factor was reduced to 2 or 3 times, so as not to interrupt the cell growth.
  • the inventor has attempted to culture the 33 rd -generation cells, which had been almost adapted to the "Opti-MEM I Reduced-Serum Medium,” in Eagle's MEM, RPMI 1640 Medium, Leiovitz's L-15 Medium, or McCoys 5A Medium.
  • the cells favorably replicated in the McCoys 5A Medium (modified) (GIBCO Base Catalogue Nos. 12330 and 16600).
  • the cell growth terminated on the mid course although they adhered to the wall of the incubation vessel. Thus, a cell sheet was not formed.
  • RPMI 1640 Medium a medium that did not contain an animal-derived protein
  • RPMI/SP medium a medium that did not contain an animal-derived protein
  • Table 1 The medium and additives as shown in the table are provided as examples, and examples of commercially available products are shown herein. Accordingly, the RPMI/SP medium of the present invention is not limited thereto.
  • RPMI/SP medium 1 A specific example of RPMI/SP medium 1) RPMI 1640 Medium (GIBCO, Catalogue No. 21870) 2) 15 g of soybean peptone (peptone from soybean, enzymatic digest, Fluka, Catalogue No. 87972) was dissolved in 1,000 ml of sterilized distilled water, and the obtained solution was then filtrated through a 220-nm filter. Thereafter, 5 ml of the filtrate was added to 100 ml of the medium of 1) (final concentration: 750 ⁇ g/ml). 3) L-glutamine was added to the above mixture to a concentration of 300 mg/l (final concentration: 300 ⁇ g/ml).
  • antibiotics potassium penicillin G, streptomycin sulfate, and amphotericin B were added to the obtained mixture to concentrations of 100 U/ml, 100 ⁇ g/ml and 2.5 ⁇ g/ml, respectively. (The aforementioned concentrations were all the final concentrations.)
  • the culture vessel used for culture was a non-glass vessel, for example, a plastic vessel such as a 25-cm 2 T flask or a plastic Petri dish with a diameter of 6 cm.
  • a plastic vessel such as a 25-cm 2 T flask or a plastic Petri dish with a diameter of 6 cm.
  • culture was initiated in a serum free culture.
  • the original wall adhesive property of MDCK cells was attenuated.
  • the cells adhered to the glass wall, but extension and replication of the cells were not observed.
  • the cells formed neither a cell mass nor a cell sheet. Accordingly, a plastic culture vessel was used in all the processes of the present invention.
  • MDCK cells which had been subcultured in the "Opti-Pro SFM” and "Opti-MEM I Reduced-Serum Medium” until the total passage number had reached 35, were then adapted to and subcultured in the medium as shown in Table 1.
  • Table 1 When the above cells were subcultured in the RPMI/SP medium until the passage number reached 28, it was confirmed that the cells were clearly adapted to the above medium, and that the cell growth could be stabilized. That is to say, the time required for formation of cell sheets and the passage intervals became constant over the past several passages, and the cells were subcultured to quantities that were 4 times the initial quantities at the intervals of 5 to 7 days.
  • the 45 th -generation cell strain was defined as a newly induced cell strain, and it was deposited with the aforementioned international institutions, as stated above (MDCK-SP strain).
  • Figure 1 shows a photograph of a cell sheet taken on the 3 rd day of the culture of the 40 th -generation MDCK-SP cell strain. The photograph was taken under an inverted microscope, while the cells were neither immobilized nor stained. Thereafter, the number of the cells further increased, and the sheet thereby became thickened.
  • Figure 2 shows the growth curb of the 41 st -generation MDCK-SP cells cultured in the RPMI/SP medium. Culture of parent cells used as controls were initiated in 7.5% MEM. In the case of both types of cells, 7.5 ml of the cell suspension having a cell concentration that had been controlled to 5.0 ⁇ 10 5 /ml was placed in a 25-cm 2 T flask, and it was then subjected to a standing culture in a closed system. The number of cells was counted every 24 hours. As shown in Figure 2, seven days later, the quantities of the MDCK-SP cells increased to approximately 4 times the original quantities thereof, and the quantities of the parent cells increased to approximately 5.5 times the original quantities thereof. From such results, it is found that the MDCK-SP cells were excellent in terms of replication, as well as the MDCK cells as parent cells.
  • the MDCK-SP cells had the following properties.
  • the MDCK-SP cells from 47 th generation were examined. As a result, it was found that the MDCK-SP cells replicated at the same level although the amount of a soybean peptone was increased.
  • the MDCK-SP cells were subjected to a suspension culture using commercially available microcarrier beads.
  • Cytodex (trade mark) 1 of Amersham Bioscience was used as commercially available microcarrier beads. This is a sphere consisting of dextran, which is specifically used in cell culture.
  • microcarrier beads 0.3 g was weighed, and it was then activated with a phosphate buffered saline that did not contain Ca ++ and Mg ++ in accordance to the instructions. Thereafter, it was sterilized by heating with an autoclave, followed by substitution with an RPMI/SP medium. This suspension of microcarrier beads was transferred into a spinner flask (Wheaton Science Products, NJ, USA). The total 10 7 MDCK-SP cells (the 56 th -generation) were then suspended in 50 ml of RPMI/SP medium, and the suspension was then placed in the flask, so that the cells were adsorbed at 37°C.
  • the suspension was occasionally rotated at 40 rpm for about 2 minutes, so that the cells were mixed with and allowed to come into contact with the sphere. Thereafter, 50 ml of RPMI/SP medium was further added to the suspension, and while the total 100 ml of the mixture was rotated in the spinner at 60 rpm, the culture was initiated.
  • FIG. 3 is a photomicrograph taken 27 days after the initiation of the culture.
  • the suspension culture method using microcarrier beads is a technique used for increasing the number of cells generated per unit volume.
  • a canine parvovirus may be replicated using the MDCK/SP cells.
  • This culture method is extremely useful for generation of a virus whose replication level depends on the replicating ability of host cells to be infected with the virus, such as a canine parvovirus. It is anticipated that the level of viruses generated will be significantly increased.
  • the level of canine parvoviruses contained in 1 vial (1 ml volume) of vaccine for dogs which is currently commercially available, is between 10 5.0 and 10 7.0 TCID 50 , the purpose can be sufficiently achieved even by a culture method involving the infectivity titers of seed virus stocks as shown in Table 2 below.
  • the suspension culture method using microcarrier beads is applied to solve such a problem specific for cell function-dependent viruses.
  • Example 3 there were used 5 types of viruses, which currently constitute core vaccines used in preventive inoculation to pet dogs widely over the world, such as canine distemper virus, canine adenovirus type 1 and type 2, canine parainfluenza virus, and canine parvovirus type 2.
  • virus stocks have been replicated in a cell culture system such as Eagle's MEM that fetal bovine serum or tryptose phosphate broth had been added.
  • animal proteins such as a bovine serum ingredient should be eliminated.
  • a serum free seed virus stock was produced in the present example.
  • Table 2 shows the actually used virus strain names, among the aforementioned virus species, and the virus titers of seed virus stocks produced using such virus strains.
  • Viruses of seed virus stocks and infectivity titers Infectivity titer (TCID 50 /0.1 ml) Virus Strain name Cell species 7.5% MEM medium RPMI/SP medium Canine distemper virus Snyder-Hill MDCK 10 4.7 10 5.5 Canine adenovirus type 1 PR109 MDCK 10 8.5 10 9 Canine adenovirus type 2 Manhattan MDCK 10 6.7 10 5.3 Canine parvovirus type 2 MD97-037 MDCK 10 5.5 10 4.5 Canine parainfluenza virus Tsukuba MDCK 10 7.7 10 8.3
  • MDCK cells as parent cells were cultured in a medium, to which 2% fetal bovine serum had been added, so as to promote replication of the viruses.
  • 2% bovine serum and 10% tryptose phosphate both are contained in the culture supernatant, the following attempt was made to eliminate the influence of such ingredients.
  • a virus stock was inoculated into MDCK-SP cells, which had been cultured in a closed system flask and had formed a cell sheet, and viruses were then adsorbed thereon for 1 hour.
  • the virus stock was eliminated by aspiration, and the cell surfaces were then washed twice with an RPMI/SP medium. Thereafter, an RPMI/SP medium was added thereto, and the obtained mixture was then subjected to a standing culture in an incubator at 37°C, so as to promote replication of viruses. A few to 7 days later, when viruses sufficiently replicated, the flask that contained the culture was once frozen and then thawed. The thawed solution was subjected to a low-speed centrifugation to remove cells and cell-debris. The supernatant was defined as a 2 nd -generation virus stock. This operation was repeated two times in total, and the obtained 3 rd -generation culture supernatant was defined as a virus stock, and it was poured in a freezer of -80°C and was preserved.
  • the virus was inoculated into the MDCK-SP cells, when the cells were suspended in an RPMI/SP medium.
  • the initial virus stock contained 7.5% fetal bovine serum, and thus the influence of the bovine serum in the initial virus stock was greater than that in other virus stocks.
  • a virus stock in an amount of approximately 5% of the culture solution was added to the suspension, and the mixed solution was then subjected to a standing culture in an incubator at 37°C. Twenty-four hours after adhesion of the cells to the wall, the culture solution was eliminated by aspiration, and the cell surfaces were washed once with an RPMI/SP medium.
  • a new RPMI/SP medium was added to the incubator to promote replication of the virus.
  • the infected cells themselves were subcultured in the same subculture operation as the subculture of normal MDCK-SP cells by digestion with trypsin. This operation was repeated twice in total, and the 3 rd -generation culture contained in a flask was once frozen and thawed. The thawed solution was subjected to a low-speed centrifugation to eliminate cells and cell debris. The supernatant was defined as a seed virus stock.
  • the infectivity titers of virus species produced in the MDCK-SP cells cultured in the RPMI/SP medium are also shown in Table 2. From Table 2, it was found that such infectivity titers are equivalent to there of the virus replicated in MDCK cells as parent cells.
  • Figure 4 shows growth curves of the canine distemper virus Snyder Hill strains in MDCK cells as parent cells cultured in 7.5% MEM and in MDCK-SP cells cultured in the medium of the present invention that contained no proteins derived from animals. From the day after virus inoculation, in both the parent MDCK cells and the MDCK-SP cells, the virus was started to be generated at 24 hours after infection, and the number of the viruses then increased. At all time points, the MDCK-SP cells exhibited virus infectivity titers that were 32 to 100 times higher than those of the MDCK cells.
  • Example 5 Canine adenovirus type 1 and type 2
  • Parvovirus has generally been known that when host cells actively divide and grow, the level of virus generated also increase. This is because parvovirus does not have a nucleic acid synthetase necessary for replication of viral DNA, and because the above virus uses the DNA polymerase of the host cells infected therewith. In the case of parvovirus, when host cells actively divide and grow, the amount of DNA polymerase also increases, and replication is thereby promoted. In the method of digesting and dispersing virus-infected cells with trypsin and then subculturing the cells in a new medium, as conducted in Example 3, the ratio of virus-infected cells increases in every passage. Thus, by such subculture of the cells, host cells also divide, and the environment is preferably changed to more efficient virus replication.
  • virus growth method may be modified by altering cell density, the level of infecting virus, the passage of virus-infected cells, etc.
  • a medium used in cell freezing was prepared by adding 10% DMSO (Wako Pure Chemical Industries, Ltd.; Catalogue No. 043-07216) to an RPMI/SP medium. MDCK-SP cells, which had been subcultured in an RPMI/SP medium until the passage number had reached 44, were suspended in the prepared medium, resulting in a concentration of 10 6 /ml or greater. Then, 1.8 ml each of the suspension was dispensed in a cryopreserving vial. The exact number of cells was found to be 6.5 ⁇ 10 6 /vial.
  • the frozen cells were removed from the liquid nitrogen according to usual methods, and the cells were then immediately thawed in warm water of approximately 40°C. Thereafter, the thawed cells were diluted and suspended in 10 ml of RPMI/SP medium, and the cells were then recovered by a low-speed centrifugation. A cell pellet was resuspended in 7.5 ml of RPMI/SP medium, and the suspension was then placed in a 25-cm 2 T flask. The culture was initiated at 37°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP05720511.4A 2005-03-10 2005-03-10 Ohne aus tieren stammende bestandteile kultivierbare zelline, verfahren zu deren realisierung, verfahren zur virusherstellung unter verwendung der zellinie sowie impstoffherstellungsverfahren Active EP1862537B1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2005/004240 WO2006095431A1 (ja) 2005-03-10 2005-03-10 動物由来の成分なしで培養可能である細胞株及びその作出方法、これを用いたウイルスの生産方法、及びワクチンの生産方法

Publications (3)

Publication Number Publication Date
EP1862537A1 true EP1862537A1 (de) 2007-12-05
EP1862537A4 EP1862537A4 (de) 2009-01-21
EP1862537B1 EP1862537B1 (de) 2013-05-08

Family

ID=36953042

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05720511.4A Active EP1862537B1 (de) 2005-03-10 2005-03-10 Ohne aus tieren stammende bestandteile kultivierbare zelline, verfahren zu deren realisierung, verfahren zur virusherstellung unter verwendung der zellinie sowie impstoffherstellungsverfahren

Country Status (6)

Country Link
US (1) US7910366B2 (de)
EP (1) EP1862537B1 (de)
JP (1) JP4693839B2 (de)
CA (1) CA2601006C (de)
ES (1) ES2424365T3 (de)
WO (1) WO2006095431A1 (de)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155168A1 (en) * 2008-06-16 2009-12-23 Intervet International B.V. Method of replicating viruses in suspension cultures of dog kidney cells
US7670837B2 (en) 2004-12-23 2010-03-02 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
WO2011098615A1 (fr) 2010-02-15 2011-08-18 Universite Claude Bernard Lyon 1 Cellules modifiees pour la production virale par l'inhibition du gene hipk2
US8202726B2 (en) 2008-09-24 2012-06-19 Medimmune, Llc Methods for cultivating cells, propagating and purifying viruses
US8357376B2 (en) 2006-09-15 2013-01-22 Memimmune, LLC Method of purifying influenza virus and removing MDCK cell DNA contaminants
WO2014105672A1 (en) * 2012-12-28 2014-07-03 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
US9878027B2 (en) 2012-12-28 2018-01-30 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
PL2114421T3 (pl) * 2007-03-05 2018-07-31 Om Pharma Ekstrakt bakteryjny do stosowania względem zaburzeń oddechowych i sposób jego wytwarzania
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
US20190078056A1 (en) * 2016-03-29 2019-03-14 The Research Foundation For Microbial Diseases Of Osaka University Method for culturing mdck cells
CN105816869A (zh) * 2016-04-26 2016-08-03 中国农业科学院特产研究所 水貂犬瘟热病毒活疫苗制备的方法及用该方法制备的疫苗

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003000A2 (en) * 1998-07-10 2000-01-20 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
WO2001023527A1 (en) * 1999-09-28 2001-04-05 Baxter Aktiengesellschaft Medium for the protein-free and serum-free cultivation of cells
EP1096017A2 (de) * 1999-10-26 2001-05-02 Welfide Corporation Verfahren zur Erhöhung der Produktion von physiologisch aktiven Substanzen in Zellkultur
US20040077086A1 (en) * 2002-07-09 2004-04-22 Manfred Reiter Animal protein free media for cultivation of cells
WO2004078955A1 (en) * 2003-03-03 2004-09-16 Glaxosmithkline Biologicals S.A. Animal-free cell culture method
WO2004110484A1 (fr) * 2003-06-18 2004-12-23 Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' Procede de production d'un vaccin vivant de culture contre le virus de la grippe

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825036B2 (en) 2000-03-03 2004-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003000A2 (en) * 1998-07-10 2000-01-20 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
WO2001023527A1 (en) * 1999-09-28 2001-04-05 Baxter Aktiengesellschaft Medium for the protein-free and serum-free cultivation of cells
EP1096017A2 (de) * 1999-10-26 2001-05-02 Welfide Corporation Verfahren zur Erhöhung der Produktion von physiologisch aktiven Substanzen in Zellkultur
US20040077086A1 (en) * 2002-07-09 2004-04-22 Manfred Reiter Animal protein free media for cultivation of cells
WO2004078955A1 (en) * 2003-03-03 2004-09-16 Glaxosmithkline Biologicals S.A. Animal-free cell culture method
WO2004110484A1 (fr) * 2003-06-18 2004-12-23 Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' Procede de production d'un vaccin vivant de culture contre le virus de la grippe

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GUT J ET AL: "Cryptosporidium parvum: in vitro cultivation in Madin-Darby canine kidney cells." THE JOURNAL OF PROTOZOOLOGY 1991 NOV-DEC, vol. 38, no. 6, November 1991 (1991-11), pages 72S-73S, XP009110058 ISSN: 0022-3921 *
MERTEN O W ET AL: "PRODUCTION OF INFLUENZA VIRUS IN CELL CULTURES FOR VACCINE PREPARATION" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, vol. 397, 1 January 1996 (1996-01-01), pages 141-151, XP000982880 ISSN: 0065-2598 *
MERTEN O-W ET AL: "PRODUCTION OF INFLUENZA VIRUS IN SERUM-FREE MAMMALIAN CELL CULTURES" DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, KARGER, BASEL, CH, vol. 98, 1 January 1999 (1999-01-01), pages 23-37, XP000990517 ISSN: 0301-5149 *
MOCHIZUKI ET AL: "Growth characteristics of canine pathogenic viruses in MDCK cells cultured in RPMI 1640 medium without animal protein" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 24, no. 11, 10 March 2006 (2006-03-10), pages 1744-1748, XP005294671 ISSN: 0264-410X *
See also references of WO2006095431A1 *
VOETEN J T ET AL: "Generation and characterization of reassortant influenza A viruses propagated in serum-free cultured MDCK-SF1 cells." DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION 1999, vol. 98, 1999, pages 77-87 ; disc, XP009110035 ISSN: 0301-5149 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7670837B2 (en) 2004-12-23 2010-03-02 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
US8119388B2 (en) 2004-12-23 2012-02-21 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
US8748174B2 (en) 2004-12-23 2014-06-10 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
US8846032B2 (en) 2006-09-15 2014-09-30 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
US8357376B2 (en) 2006-09-15 2013-01-22 Memimmune, LLC Method of purifying influenza virus and removing MDCK cell DNA contaminants
US9441207B2 (en) 2008-06-16 2016-09-13 Intervet Inc. Method of replicating viruses in suspension cultures of dog kidney cells
WO2009155168A1 (en) * 2008-06-16 2009-12-23 Intervet International B.V. Method of replicating viruses in suspension cultures of dog kidney cells
US8202726B2 (en) 2008-09-24 2012-06-19 Medimmune, Llc Methods for cultivating cells, propagating and purifying viruses
US9085753B2 (en) 2008-09-24 2015-07-21 Medimmune, Llc Methods for cultivating cells, propagating and purifying viruses
WO2011098615A1 (fr) 2010-02-15 2011-08-18 Universite Claude Bernard Lyon 1 Cellules modifiees pour la production virale par l'inhibition du gene hipk2
WO2014105672A1 (en) * 2012-12-28 2014-07-03 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
US9273281B2 (en) 2012-12-28 2016-03-01 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
US9878027B2 (en) 2012-12-28 2018-01-30 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
EA032772B1 (ru) * 2012-12-28 2019-07-31 Бёрингер Ингельхайм Ветмедика Гмбх Способ получения иммуногенной композиции, предназначенной для лечения и/или профилактики вызываемых микоплазмами инфекций у субъекта
US10512680B2 (en) 2012-12-28 2019-12-24 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
US10758602B2 (en) 2012-12-28 2020-09-01 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens

Also Published As

Publication number Publication date
US20080138362A1 (en) 2008-06-12
EP1862537A4 (de) 2009-01-21
CA2601006C (en) 2012-10-23
JP4693839B2 (ja) 2011-06-01
ES2424365T3 (es) 2013-10-01
CA2601006A1 (en) 2006-09-14
WO2006095431A1 (ja) 2006-09-14
US7910366B2 (en) 2011-03-22
JPWO2006095431A1 (ja) 2008-08-14
EP1862537B1 (de) 2013-05-08

Similar Documents

Publication Publication Date Title
EP1862537B1 (de) Ohne aus tieren stammende bestandteile kultivierbare zelline, verfahren zu deren realisierung, verfahren zur virusherstellung unter verwendung der zellinie sowie impstoffherstellungsverfahren
JP5264812B2 (ja) Ｍｄｃｋ細胞懸濁培養物において薬物または診断剤の活性成分を生成する方法
AU2002338666B2 (en) Multiplication of viruses in a cell culture
JP2012005502A (ja) インフルエンザウイルスの複製のための動物細胞および方法
JP2011212020A (ja) 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス
JP6110357B2 (ja) イヌ腎細胞の浮遊培養物においてウイルスを複製する方法
Arifin et al. Production of Newcastle disease virus by Vero cells grown on cytodex 1 microcarriers in a 2‐litre stirred tank bioreactor
US7767451B2 (en) Feline cell capable of being cultured without animal-derived protein, and method for producing virus and method for producing vaccine using thereof
EP3925620A1 (de) Proliferationsverfahren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070926

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT NL

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT NL

A4 Supplementary search report drawn up and despatched

Effective date: 20081223

17Q First examination report despatched

Effective date: 20090928

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602005039483

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12N0005060000

Ipc: C12N0005070000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101ALI20120330BHEP

Ipc: C12N 5/02 20060101ALI20120330BHEP

Ipc: C12N 5/07 20100101AFI20120330BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE ES FR GB IT NL

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005039483

Country of ref document: DE

Effective date: 20130704

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2424365

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20131001

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20140211

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005039483

Country of ref document: DE

Effective date: 20140211

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230404

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240320

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240320

Year of fee payment: 20

Ref country code: GB

Payment date: 20240313

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240320

Year of fee payment: 20

Ref country code: FR

Payment date: 20240313

Year of fee payment: 20